Knocked Out by Nasdaq

Premium

By Jennifer Friedlin

The Nasdaq has been about as unkind to genomics companies so far this year as it was kind to them in 2000. On January 23, genomics Judgment Day, the Nasdaq slashed from 202 to 76 the number of companies in its Biotechnology Index for failure to meet a handful of criteria. Among these companies were six members of the GTI: Compugen, DeCode, InforMax, Lynx Therapeutics, Rosetta Inpharmatics, and Variagenics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.